Adverse Metabolic Effects of Antihypertensive Drugs Implications for Treatment

Drug Safety

Volumn 14, Issue 6, 1996, Pages 355-364

  Preuss, Harry G ^a   Burris, James F ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INSULIN; LIPID; LISINOPRIL; PINDOLOL; PROPRANOLOL; RESERPINE; URIC ACID;

ALKALOSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; ELECTROLYTE DISTURBANCE; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INSULIN METABOLISM; LIPID BLOOD LEVEL; META ANALYSIS; METABOLIC DISORDER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; METABOLISM;

EID: 0030011513     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199614060-00001     Document Type: Article

References (93)

1. Black HR. Metabolic considerations in the choice of therapy for the patient with hypertension. Am Heart J 1991; 1231: 707-5
2. Houston MC. Hypertension strategies for therapeutic intervention and prevention of end-organ damage. Prim Care 1991; 18: 713-53
3. Wilson MD, Weart CW. Hypertension: Are β-blockers and diuretics appropriate first-line therapies? Ann Pharmacother 1994; 28: 617-25
4. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short term reductions in blood pressure: overview of randomized trials in their epidemiological context. Lancet 1990; 335: 827-38
5. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: Results in patients a with diastolic pressures averaging 115 through 129 mm Hg. JAMA 1967; 202: 1028-34
6. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program II. Mortality by race, sex, and age. JAMA 1976; 242: 2572-7
7. The Australian therapeutic trial in mild hypertension. Report of the management committee. Lancet 1980; I: 1261-7
8. Applegate WB. Hypertension in elderly patients. Ann Intern Med 1989; 110: 901-15
9. SHEP Cooperative Study Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-64
10. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure, the fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-83
11. Burris JF. Beyond controlling blood pressure in the black patient: metabolic considerations. J Natl Med Assoc 1995; 87: 1-4
12. Cruickshank JM, Thorpe JM, Zacharias FJ. Benefits and potential harm of lowering blood pressure. Lancet 1987; I: 581-4
13. Moser M, Menard J. Clinical significance of the metabolic effects of antihypertensive drugs. J Hum Hypertens 1993; 7 Suppl. 1: S50-S55
14. Gorlin R. Do we need another antihypertensive agent? Am Heart J 1991; 121: 670-6
15. Nilsson P, Andersson DKG, Andersson P-E, et al. Cardiovascular risk factors in treated hypertensives - a nation-wide, cross sectional study in Sweden. J Intern Med 1993; 233: 239-45
16. Freis ED, Wanko A, Wilson IM, Parrish AE. Chlorothiazide in hypertensive and normotensive patients. Ann NY Acad Sci 1958; 71: 450-5
17. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propanolol and hydrochlorothiazide for the initial treatment of hypertension. I: Results of short-term titration with emphasis on racial differences in response. JAMA 1982; 248: 1996-2003
18. Carney SL, Gillies A, Morgan TO. Optimal dose of a thiazide diuretic. Med J Aust 1976; 2: 692-3
19. Siskovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852-7
20. Latta K, Hisano S, Chan JCM. Perturbations in potassium balance. In: Preuss HG, editor. Clinics in Laboratory Medicine. Philadelphia: Saunders, 1993: 149-56
21. Papademetriou V. Diuretics in hypertension: clinical experiences. Eur Heart J 1992; 13 Suppl. G: 92-5
22. Holland OB, Nixon JV, Kuhnert I. Diuretic induced ventricular ectopic activity. Am J Med 1981; 70: 762-8
23. Multiple Risk Factor Intervention Trial Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol 1985; 55: 1-15
24. Hollifield JW. Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension. Am J Med 1984; 77: 28-32
25. Hollifield JW, Slaton PE. Thiazide diuretics, hypokalemia, and cardiac arrhythmias. Acta Med Scand 1981; 647 Suppl: 67-73
26. Abraham AS, Rosenman D, Neahulam, et al. Serum, lymphocyte, and erythrocyte potassium, magnesium, and calcium concentrations and their relation to tachyarrhythmias in patients with acute myocardial infarction. Am J Med 1986; 81: 983-8
27. Cohen JD, Neaton JD, Prineas RJ, et al. Diuretics, serum potassium and ventricular arrhythmias in Multiple Risk Factor Intervention Trial. Am J Cardiol 1987; 60: 548-54
28. Papademetriou V. Diuretic hypokalemia and cardiac arrhythmias: a critical analysis. Am Heart J 1986; 111: 1217-24
29. Papademetriou V, Burris JF, Notargiacomo A, et al. Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension. Arch Intern Med 1988; 148: 1272-6
30. Madias J, Madias NE, Gavras HP. Non-arrhythmogenicity of diuretic-induced hypokalemia. Arch Intern Med 1984; 144: 2171-6
31. Siegel D, Hulley SB, Black DM, et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA 1992; 267: 1083-9
32. Seelig M, Preuss HG. Magnesium metabolism in the aging. J Ger Nephrol and Urol 1994; 4: 101-11
33. Delaney V, Preuss HG. Hypomagnesemia. In: Hurst JW, editor. Criteria for diagnosis. Boston: Butterworth, 1989: 428
34. Fichman MP, Vorherr H, Kleeman CR, et al. Diuretic induced hyponatremia. Ann Intern Med 1971; 75: 853-63
35. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-7
36. Reaven GM, Hoffman BB. A role for insulin in the aetiology and course of hypertension? Lancet 1987; II: 435-6
37. Fuh MM-T, Shieh S-M, Wu D-A, et al. Abnormalities of carbohydrate and lipid metabolism in patients with hypertension. Arch Intern Med 1987; 147: 1035-8
38. Reaven GM. Role of insulin resistance in human disease [Banting Lecture 1988]. Diabetes 1988; 37: 1595-607
39. Fournier AM, Gadia MT, Kubrusly DB, et al. Blood pressure, insulin, and glycaemia in nondiabetic subjects. Am J Med 1983; 80: 861-4
40. Solt VB, Brown MR, Kennedy B, et al. Elevated insulin, norepinephrine, and neuropeptide Y in hypertension. Am J Hypertens 1990; 3: 823-8
41. Krotkiewski M, Mandroukas K, Sjostrom L, et al. Effects of long-term physical training on body fat, metabolism and blood pressure in obesity. Metabolism 1979; 28: 650-8
42. Supiano MA, Hogikyan RV, Morrow LA, et al. Aging and insulin sensitivity: role of blood pressure and sympathetic nervous system activity. J Gerontol Med Sci 1993; 48: M237-M243
43. DeFronzo RA. Insulin and renal sodium handling: clinical implications. Int J Obes 1981; 5 Suppl. 1: 93-104
44. Rochini AP, Katch V, Kveselis K, et al. Insulin and renal sodium retention in obese adolescents. Hypertension 1989; 14: 367-74
45. Rowe JW, Young JB, Minaker KL, et al. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219-25
46. Sower JR. Is hypertension an insulin-resistant state? Metabolic changes associated with hypertension and antihypertensive therapy. Am Heart J 1991; 122: 932-5
47. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM. obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94
48. Cerami A, Vlassare H, Brownlee M. Glucose and aging. Sci Am 1987; 256: 90-6
49. Murphy MB, Lewis PJ, Kohner E, et al. Glucose intolerance in hypertensive patients treated with diuretics, a fourteen year follow-up. Lancet 1982; II: 1293-5
50. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-73
51. Ramsay LE, Yeo WW, Jackson PR. Influence of diuretics, calcium antagonists, and α-blocker on insulin sensitivity and glucose tolerance in hypertensive patients. J Cardiovasc Pharmacol 1992; 209 Suppl. 11: S49-S54
52. Skarfors ET, Lithell HO, Selinus I, et al. Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ 1989; 298: 1147-52
53. Lundgren H, Bjorkman L, Keiding P, et al. Diabetes in patients with hypertension receiving pharmacological treatment. BMJ 1988; 297: 1512
54. Burris JF. β-Blockers, dyslipidemia, and coronary artery disease. A reassessment. Arch Intern Med 1993; 153: 2085-92
55. Bengtsson C, Blohme G, Lapidus L, et al. Do antihypertensive drugs precipitate diabetes? BMJ 1984; 289: 1495-7
56. Skafors ET, Lithel HO, Selinus I. Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ 1989; 298: 1147-51
57. DeCesaris R, Ranieri G, Filitti V, et al. Glucose and lipid metabolism in essential hypertension: Effects of diuretics and ACE-inhibitors. Clin Pharm 1993; 83: 165-72
58. Scali M, Armanini D, Mamtero F, et al. Metabolic effects of lisinopril versus hydrochlorothiazide plus amiloride in essential hypertension. Curr Ther Res 1992; 52: 397-405
59. Ross H. Prazosin, diuretics, and glucose intolerance. Ann Intern Med 1993; 119: 859-60
60. Gurwitz MK, Barke J, Gustafson AB, et al. Drug-induced disorders of glucose intolerance [letter]. Ann Intern Med 1993; 118: 529-19
61. Sawicki P. Guidelines for management of hypertension. Metabolic effects of drug treatment exaggerated [letter]. BMJ 1994; 308: 855
62. Grimm Jr RH. Treating hypertension and cardiovascular risk: Are there trade-offs? Am Heart J 1990; 119: 729-32
63. Grimm RH. Lipid effects on antihypertensive agents: an overview. Choices Cardiol 1988; 2: 208-10
64. Morgan TO. Metabolic effects of various antihypertensive agents. J Cardiovasc Pharmacol 15; 1990: Suppl. 5: S39-S45
65. Schaper H, Fitz A, Frohlich E, et al. Chlorthalidone and serum cholesterol [letter]. Lancet 1977; II: 295
66. Goldman AL, Steele BW, Schapner, et al. Serum lipoprotein levels during chlorthalidone therapy. JAMA 1980; 244: 1691-5
67. Grimm RH, Leon AS, Hunningshake DB, et al. Effect of thiazide diuretics on blood lipids and lipoprotein in mildly hypertensive patients. A double-blind control trial. Ann Intern Med 1981; 94: 7-11
68. Freis ED. The efficacy and safety of diuretics in treating hypertension. Ann Intern Med 1995; 122: 223-6
69. Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med 1988; 148: 1280-8
70. Beling S, Vukovich RA, Neiss ES, et al. Long-term experience with indapamide. Am Heart J 1983; 106: 258-62
71. Gerber A, Weidmann P, Branchetti MG. Serum lipoproteins during treatment with the antihypertensive agent indapamide. Hypertension 1985; 7 Suppl. 2: 164-9
72. Elliot WJ, Weber RR, Murphy MB. A double-blind, randomized, placebo-controlled comparison of the metabolic effects of low-dose hydrochlorothiazide and indapamide. J Clin Pharmacol 1991; 31: 751-7
73. Waal-Manning HJ. Metabolic effects of indapamide [letter]. NZ Med J 1990; 103: 20
74. Ames RP. Hyperlipidemia in hypertension: causes and prevention. Am Heart J 1991; 122: 1219-24
75. Van Brummelen P. The relevance of intrinsic sympathomimetic activity for β-blocker-induced changes in plasma lipids. J Cardiovasc Pharmacol 1983; 5 Suppl. 1: S51-S55
76. Swales JD. Guidelines for management of hypertension. Sticking to the guidelines can be expensive [letter]. BMJ 1994; 308: 855
77. Deleu D, Bohle K. Metoprolol as antihypertensive drug. Am J Cardiol 1991; 68: 831-2
78. Ferrara LA, Marotta T, Scilla A, et al. Effect of oxprenolol and metoprolol on serum lipid concentration. Eur J Clin Pharmacol 1978; 13: 5-8
79. Nilsson A, Hanson BG, Hokfelt B. Effect of metoprolol on blood glycerol, free fatty acids, triglycerides and glucose in relation to plasma catecholamines in hypertensive patients at rest and following submaximal work. Eur J Clin Pharmacol 1978; 13: 5-8
80. Lind L, Pollare T, Berne C, Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994; 128: 1177-83
81. Weinburger MH. Influence of angiotensin-converting enzyme inhibitor on diuretic induced metabolic effects in hypertension. Hypertension 1983; 5 Suppl. 3: 132-8
82. Costa FV, Borghi C, Ambrosioni E. Hypolipemic effects of long-term antihypertensive treatment with captopril. Am J Med 1988; 84 Suppl. 3A: 159-61
83. Midtbo KA. Effects of long-term verapamil therapy on serum lipids and other metabolic parameters. Am J Cardiol 1990; 66: 131-51
84. Houston MC. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J 1988; 115: 640-56
85. Pollare T, Lithell H, Selinus I. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415-20
86. Swislocki ALM, Hoffman BB, Sheu WH-H, et al. Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. Am J Med 1989; 86: 14-8
87. Deger G. Effect of terazosin on serum lipids. Am J Med 1986; 80 Suppl. 5B: 82-5
88. Leren P, Eide I, Foss OP, et al. Antihypertensive drugs and blood lipids. The Oslo Study. J Cardiovasc Pharmacol 1982; 4 Suppl. 1: S222-S224
89. Okun R, Kraut J. Prazosin versus captopril as initial therapy. Effect on hypertension and lipid levels. Am J Med 1987; 82 Suppl. 1A: 58-63
90. Aranda P, Lopez de Novales E. Diuretics and the treatment of systemic hypertension. Am J Cardiol 1990; 65: 72H-6H
91. Langford HG, Blaufox MD, Borhani NO, et al. Is thiazide produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 1987; 147: 645-9
92. Poulter N, Sever P, Thom S. Antihypertensive and adverse biochemical effects of bendrofluazide [letter]. BMJ 1990; 300: 1465-6
93. Johnston GD, Sever PS. Antihypertensive and adverse biochemical effects of bendrofluazide [letter & reply]. BMJ 1990; 301: 42-3